Detalhe da pesquisa
1.
Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.
Mol Med
; 20: 46-56, 2014 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24395569
2.
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
Carcinogenesis
; 30(11): 1848-56, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19762335
3.
Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Mol Pharmacol
; 73(3): 627-38, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18025070
4.
Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Cancer Res
; 66(24): 11831-9, 2006 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17178880
5.
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Clin Cancer Res
; 12(17): 5064-73, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16951222
6.
Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines.
J Chem Biol
; 10(3): 129-141, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28684999
7.
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
J Clin Invest
; 126(1): 169-80, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26619122
8.
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Neoplasia
; 17(3): 256-64, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25810010
9.
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
Oral Oncol
; 48(11): 1136-45, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22732263
10.
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Neoplasia
; 14(11): 1005-14, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23226094
11.
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Clin Cancer Res
; 18(20): 5639-49, 2012 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22929803
12.
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Autophagy
; 8(12): 1873-4, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22995770
13.
Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
Mol Cancer Ther
; 11(6): 1236-46, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22491800
14.
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.
Cancer Discov
; 2(8): 694-705, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22719020
15.
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.
Cancer Prev Res (Phila)
; 4(2): 230-7, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21163936
16.
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
J Clin Invest
; 126(4): 1606, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27035818